Feasibility trial of UFT [tegafur/uracil] after withdrawal of adjuvant TS-1 [S 1] with adverse effects in patients with curatively resected gastric cancer

Trial Profile

Feasibility trial of UFT [tegafur/uracil] after withdrawal of adjuvant TS-1 [S 1] with adverse effects in patients with curatively resected gastric cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Tegafur/uracil (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2010 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
    • 29 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top